Corpus Intelligence IC Memo — MEMORIAL HOSPITAL OF GARDENA 2026-04-26 12:36 UTC
IC Memo — MEMORIAL HOSPITAL OF GARDENA
Investment Committee Memorandum | CA | 103 beds | Grade C | EBITDA uplift $10.4M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

MEMORIAL HOSPITAL OF GARDENA

CCN 050468 | LOS ANGELES, CA | 103 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

MEMORIAL HOSPITAL OF GARDENA is a 103-bed under-performing / distressed in LOS ANGELES, CA with $140.9M in net patient revenue and a -33.7% operating margin. The hospital serves a payer mix of 21.0% Medicare, 9.8% Medicaid, and 69.3% commercial.

Thesis: Undervalued. Our ML models identify $10.4M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -33.7% to -26.3% (+736bps).

Net Revenue HCRIS$140.9M
Current EBITDA COMPUTED$-47.4M
Operating Margin COMPUTED-33.7%
Occupancy HCRIS70.6%
Revenue / Bed COMPUTED$1.4M
Net-to-Gross HCRIS18.7%
Distress Probability ML43.0%

2. Market Context & Competitive Position

414
CA Hospitals
-4.9%
State Median Margin
170
Comparable Hospitals

CA has 414 Medicare-certified hospitals with a median operating margin of -4.9%. The target's margin of -33.7% places it below the state median. Among 170 size-comparable peers (52-206 beds), the median margin is -4.5%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (52-206), prioritizing same-state peers. 170 hospitals in the comp set.

HospitalStateBedsRevenueMargin
MEMORIAL HOSPITAL OF GARDENA (Target)CA103$140.9M-33.7%
CHILDRENS HOSP & RES CNTR OAKLCA155$687.9M-7.1%
NORTHBAY HOSPITAL GROUPCA204$676.6M-8.2%
CONTRA COSTA REGIONAL MEDICAL CA124$595.0M-29.2%
KFH - VALLEJOCA184$531.7M0.3%
RANCHO LOS AMIGOS NATL.REHAB.CCA83$512.6M41.9%
DOMINICAN HOSPITALCA202$499.0M5.0%
CMH OF SAN BUENAVENTURACA170$498.5M-7.6%
USC NORRIS CANCER HOSPITALCA60$468.7M19.1%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $10.4M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$3.0M+210bp18mo
Cost to Collect4.5%2.5%$2.8M+200bp12mo
Denial Rate Reduction12.0%6.5%$2.8M+198bp12mo
A/R Days Reduction5200.0%3800.0%$1.7M+122bp9mo
Clean Claim Rate88.0%96.0%$90K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$3.0M
Cost to Collect
$2.8M
Denial Rate Reduction
$2.8M
A/R Days Reduction
$1.7M
Clean Claim Rate
$90K
Total EBITDA Uplift$10.4M
Current EBITDA$-47.4M
+ RCM Uplift+$10.4M
Pro Forma EBITDA$-37.1M
Current Margin-33.7%
Pro Forma Margin-26.3%
WC Released (1x)$5.4M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-73.0M$-209.2M0.00x-100.0%
Base (11x exit)10.0x11.0x$-73.0M$-253.8M0.00x-100.0%
Bull Case9.0x11.0x$-65.7M$-243.3M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-65.7M$-284.8M0.00x-100.0%
Bear Case11.0x10.0x$-80.3M$-237.3M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-80.3M$-287.1M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 170 hospitals with 52-206 beds
  • Same-state prioritization (n=171)
  • Comp margins: P25=-20.3% / P50=-4.5% / P75=4.4%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.